Industry Notice- Altrenogest Update

09 April 2024


In 2018, Australian harness racing participants were advised to cease using products containing Altrenogest after a number of horses returned positive swabs to the banned androgenic anabolic steroids Trendione and Trenbolone whilst being administered products containing Altrenogest such as ReguMate, OvuMate, ReadyServe etc…

Commercial products containing Altrenogest are used for oestrus suppression in fillies and mares and can contain traces of Trenbolone and/or Trendione.  Trenbolone and Trendione are androgenic anabolic steroids and are classed as permanently banned substances under the Australian Harness Racing Rules (AHRR’s).

 When these androgenic anabolic steroids are detected in sample taken at any time from a horse, they are regarded as permanently banned prohibited substances regardless of how or why they came to be present, and such horses are therefore subject to the AHRR provisions relating to androgenic anabolic steroids, which include that those horses are not permitted to start in a race (or trial), OR be used for the purposes of breeding for a 12-month period from the date of the collected sample. The trainer may also be subject to offences and penalties under the AHRR’s relating to anabolic steroids.

Recognising the widespread use of Altrenogest in the industry, Harness Racing Australia (HRA) is a partner in the Maintaining Welfare and Integrity in Australian Racing (research) Project, which investigates the absorption, distribution, metabolism and excretion (pharmacokinetics) of a range of important therapeutic drugs, with Altrenogest amongst them.

The Altrenogest research, led by Dr Glenys Noble from Charles Sturt University (CSU) in collaboration with racing forensic laboratories, racing codes and AgriFutures, was wide ranging, examining both the oral and injectable forms of the product, plus topical administration routes.

The research showed that there was always the possibility of trendione, epitrenbolone or trenbolone being detected when using products containing Altrenogest.

HRA consequently recommends against using any products containing Altrenogest, including injectable or compounded oral Altrenogest products.

Should a trainer elect to use Altrenogest products in racing horses, they do so at their own risk.  Trainers are also reminded of the requirement for all treatments to be recorded in their medication logbooks by midnight on the day on which the treatment was given.

The research also found Altrenogest to be easily absorbed topically, illustrating a need for humans to handle and administer Altrenogest related products with extreme care given the potential to contaminate other horses, and even themselves.

If you have any queries, or would like further information regarding this matter, please contact Stewards in your State.



Related News

14 June 2024
INDUSTRY NOTICE – 22/23 Stallion Registration Data
The 2022/23 Breeding Season saw the advent of restructured Stallion Registration processes and associated Fees managed by Harness Racing Australia (HRA) for the first time. In total, 177 Stallions registered for the Season. Of these, 119 were Pacing Sires and 58 Trotters. Of these, 24 (or 20%) of registered...
28 May 2024
QLD - Redcliffe Gold Cup eligibility reminder
As a reminder to the eligibility conditions for the Group Two $106,070 Redcliffe Gold Cup, to be eligible for selection in the Redcliffe Gold Cup a horse must have had at least one (1) Standing Start race in the last 8 months. A month out from the Cup limited opportunities remain to meet this requirement....
28 May 2024
QLD - 2024 Pacers Standing Start Season
23 May 2024
Redcliffe Track Lights Upgrade
As recently announced the Redcliffe Harness Racing Club's track flood lighting will undergo a $6m upgrade including the installation of LED lights. Throughout the project the Club and RQ will work with the contractor to keep racing operational, however some changes will be necessary to complete the...
Click for more